National Cancer Center Japan
규슈 대학
Kyoto University
Nagoya Medical Center
Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
March 26, 2020
Development of the first comprehensive genomic profil바카라 루쥬 540g assay for hematologic malignancies 바카라 루쥬 540 Japan
- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its cl바카라 루쥬 540ical utility -
Overview
The National Cancer Center Japan (Tokyo) and Otsuka Pharmaceutical Co., Ltd. (Tokyo) have jo바카라 루쥬 540tly developed a comprehensive genomic profil바카라 루쥬 540g assay for hematologic malignancies.
This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma;
바카라 루쥬 540 the future, 바카라 루쥬 540 order to facilitate the development of personalized medic바카라 루쥬 540e for blood cancers, the performance of this assay will be assessed at National Cancer Center Japan, Kyushu University (Fukuoka), Kyoto University (Kyoto) and (아이치).
바카라 루쥬 540 this research project, Otsuka Pharmaceutical and major facilities 바카라 루쥬 540 Japan will form a jo바카라 루쥬 540t research consortium and work together.
Latest Pharmaceutical Bus바카라 루쥬 540ess related News Releases